Insider Selling: Korro Bio (NASDAQ:KRRO) CEO Sells 15,152 Shares of Stock

Korro Bio, Inc. (NASDAQ:KRRO) CEO Ram Aiyar sold 15,152 shares of the stock in a transaction on Friday, May 29th. The shares were sold at an average price of $12.98, for a total transaction of $196,672.96. Following the transaction, the chief executive officer owned 74,848 shares in the company, valued at $971,527.04. This trade represents a 16.84% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Korro Bio Price Performance

NASDAQ KRRO opened at $12.93 on Tuesday. Korro Bio, Inc. has a 12 month low of $5.20 and a 12 month high of $55.89. The company has a market capitalization of $186.49 million, a price-to-earnings ratio of -1.11 and a beta of 3.07. The company’s fifty day moving average price is $12.37 and its two-hundred day moving average price is $10.63.

Korro Bio (NASDAQ:KRRO) last posted its quarterly earnings data on Thursday, May 7th. The company reported ($1.69) EPS for the quarter, missing analysts’ consensus estimates of ($1.60) by ($0.09). Korro Bio had a negative net margin of 1,834.48% and a negative return on equity of 117.86%. As a group, analysts anticipate that Korro Bio, Inc. will post -5.38 EPS for the current year.

Key Korro Bio News

Here are the key news stories impacting Korro Bio this week:

• Positive Sentiment: Lifesci Capital reiterated a Strong-Buy view on Korro Bio and issued multiple forward EPS estimates that were generally better than the broader consensus, which can support investor confidence in the stock’s long-term outlook.
• Neutral Sentiment: The analyst firm also published updated estimates across several periods, including Q2 2026, Q3 2026, Q4 2026, FY2026, FY2027, FY2028, FY2029, and FY2030, but these forecasts still point to ongoing losses as Korro Bio remains a pre-profit biotech company.
• Negative Sentiment: CEO Ram Aiyar sold 15,152 shares at an average price of $12.98, cutting his ownership by 16.84%; the company said the sale was to cover tax withholding tied to vesting equity awards, but insider selling can still weigh on sentiment.
• Negative Sentiment: Director Jean Francois Formela sold 2,860 shares at $13.95 under a pre-arranged Rule 10b5-1 trading plan, reducing his position by 1.45%, adding to the recent insider-selling narrative around KRRO.

Institutional Trading of Korro Bio

A number of large investors have recently modified their holdings of KRRO. Affinity Asset Advisors LLC acquired a new stake in shares of Korro Bio in the 1st quarter worth about $8,002,000. Nantahala Capital Management LLC acquired a new stake in shares of Korro Bio in the 4th quarter worth about $4,806,000. ADAR1 Capital Management LLC acquired a new stake in shares of Korro Bio in the 1st quarter worth about $6,113,000. TCG Crossover Management LLC acquired a new stake in shares of Korro Bio in the 3rd quarter worth about $19,937,000. Finally, JPMorgan Chase & Co. increased its holdings in shares of Korro Bio by 6,185.5% in the 3rd quarter. JPMorgan Chase & Co. now owns 199,249 shares of the company’s stock worth $9,542,000 after acquiring an additional 196,079 shares during the period. Institutional investors and hedge funds own 13.18% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have commented on KRRO shares. Raymond James Financial upgraded shares of Korro Bio from a “market perform” rating to an “outperform” rating and set a $23.00 price objective on the stock in a research note on Friday, March 13th. JonesTrading upgraded shares of Korro Bio from a “hold” rating to a “strong-buy” rating in a research note on Friday, May 8th. Clear Str upgraded shares of Korro Bio from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, February 18th. Cantor Fitzgerald raised their price target on shares of Korro Bio from $21.00 to $22.00 and gave the stock an “overweight” rating in a research report on Friday, March 13th. Finally, Lifesci Capital upgraded shares of Korro Bio to a “strong-buy” rating in a research report on Friday. Three analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $16.71.

Korro Bio Company Profile

Korro Bio, Inc is a clinical-stage biotechnology company focused on harnessing advanced protein engineering and synthetic biology to develop novel enzyme therapies and live microbial therapeutics. The company’s proprietary platform integrates directed evolution, high-throughput screening and computational design to optimize biological catalysts for a wide range of applications. By combining machine learning with experimental biology, Korro Bio seeks to accelerate the discovery and development of next-generation treatments for rare genetic disorders and complex metabolic diseases.

The company’s pipeline features both engineered enzyme therapeutics and live biotherapeutics.